title: High-Dose Chemotherapy for Adult-Type Ovarian Granulosa Cell Tumors: A Retrospective Study of the European Society for Blood and Marrow Transplantation.
abstract: A few small retrospective series reported results with salvage chemotherapy for malignant ovarian adult-type granulosa cell tumors (GCTs), whereas no data are available on high-dose chemotherapy (HDC) with hematopoietic progenitor cell support (HSCS) in these patients. The aim of this study was to analyze the available data of HDC for adult-type GCTs.
  
  
  
  We conducted a retrospective analysis of ovarian cancer treated with salvage HDC registered with the European Society for Blood and Marrow Transplantation.
  
  
  
  Of 203 adult female patients with a diagnosis of nonepithelial ovarian cancer treated with salvage HDC with HSCS and registered with the European Society for Blood and Marrow Transplantation, 4 (2%) patients were affected by GCTs. All 4 patients had ovarian adult-type GCTs that relapsed/progressed after first-line chemotherapy. The conditioning regimens included a platinum agent in all 4 patients. Bone marrow recovery was promptly achieved; neither treatment-related deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months, all patients reported a progressive disease. The patient who underwent multicycle HDC enjoyed a long-term remission of 84 months before progression and is the only one alive after 94+ months.
  
  
  
  We showed for the first time a case with long-lasting response to salvage multicycle HDC and HSCS in adult-type GCTs.
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Ugo
authors.initials: U
authors.lastname: De Giorgi
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Nicolas-Virelizier
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Manuela
authors.initials: M
authors.lastname: Badoglio
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Peter
authors.initials: P
authors.lastname: Bader
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Richard
authors.affiliation: *Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy; †Centre Leon Berard, Lyon; and ‡EBMT Paris Office, Paris, France; §Universitatsklinikum Frankfurt, Frankfurt, Germany; ∥Hopital Tenon, Paris, France; ¶University Hospital Gasthuisberg, Leuven, Belgium; and #Hematology Unit, Ravenna Hospital, Ravenna; and **Ospedale di Busto Arsizio, Varese, Italy.
authors.forename: Johan
authors.initials: J
authors.lastname: Maertens
authors.forename: Francesco
authors.initials: F
authors.lastname: Lanza
authors.forename: Marco
authors.initials: M
authors.lastname: Bregni
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000628:therapy*; D012189:Retrospective Studies; D016879:Salvage Therapy; D019172:Transplantation Conditioning / Q000379:methods*; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds